Perrigo Company plc (PRGO)
Automate Your Wheel Strategy on PRGO
With Tiblio's Option Bot, you can configure your own wheel strategy including PRGO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRGO
- Rev/Share 30.9155
- Book/Share 32.1047
- PB 0.4404
- Debt/Equity 0.8605
- CurrentRatio 2.5139
- ROIC -0.0087
- MktCap 1946003487.0
- FreeCF/Share 1.9596
- PFCF 7.1702
- PE -37.8068
- Debt/Assets 0.3794
- DivYield 0.082
- ROE -0.0118
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PRGO | JP Morgan | Overweight | Neutral | -- | $20 | Nov. 6, 2025 |
| Downgrade | PRGO | Argus | Buy | Hold | -- | -- | Jan. 14, 2025 |
| Downgrade | PRGO | Piper Sandler | Overweight | Neutral | $34 | $27 | Jan. 6, 2025 |
| Resumed | PRGO | Jefferies | -- | Hold | $50 | $30 | Sept. 24, 2024 |
News
Perrigo (PRGO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Perrigo (PRGO) Q4 Earnings Beat Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Perrigo (PRGO) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.86 per share a year ago.
Read More
Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN , Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic growth of 0.7% was more than offset by unfavorable impacts from divested businesses and exited …
Read More
What's in Store for These 5 Biotech Stocks This Earnings Season?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
Perrigo Increases Quarterly Dividend by 5%
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , Feb. 19, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend.
Read More
About Perrigo Company plc (PRGO)
- IPO Date 1991-12-17
- Website https://www.perrigo.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Patrick Lockwood-Taylor
- Employees 8379